NFC
MREO

Northeast Financial Consultants’s Mereo BioPharma MREO Stock Holding History

Northeast Financial Consultants’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,667
Closed -$60K – 336
2020
Q4 		$60K Hold
16,667
– – 0.01% 316
2020
Q3 		$44K Buy
+16,667
New +$48.7K ﹤0.01% 298

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Northeast Financial Consultants's MREO Position: Q1 2021 in Review

Northeast Financial Consultants sold out of Mereo BioPharma (MREO) in Q1 2021, closing a stake of 16,667 shares — an estimated $60K sold.

Northeast Financial Consultants first reported a position in MREO in Q3 2020 and held it in 2 quarters. The position peaked at $60K in Q4 2020. 66 funds tracked by Wall St. Rank hold MREO as of Q1 2021.

  • Northeast Financial Consultants reported no remaining Mereo BioPharma position as of Q1 2021 after selling out during the quarter.
  • Northeast Financial Consultants sold 16,667 Mereo BioPharma shares in Q1 2021, an estimated $60K.
  • Northeast Financial Consultants first reported a position in Mereo BioPharma in Q3 2020 and held it in 2 quarters.
  • Northeast Financial Consultants's Mereo BioPharma position peaked at $60K in Q4 2020.
  • 66 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2021.

Based on Northeast Financial Consultants's 13F filing for Q1 2021, filed 13 May 2021.